Novartis AG (NYSE:NVS)
| 84.57 BATS BZX Real-Time Price As of 3:42pm ET |  +0.43 / +0.51%Today’s Change | 69.18 Today|||52-Week Range 99.84 | -10.69% Year-to-Date |
Latest NVS News | Press Releases
| Bristol-Myers' Acquisition of Bluebird Seems to Make Sense Oct 20 / GuruFocus News - Paid Partner Content | Top Research Reports for Novartis, Zoom Video & FIS Oct 16 / Zacks.com - Paid Partner Content |
| AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU Oct 20 / Zacks.com - Paid Partner Content | Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak Oct 15 / Zacks.com - Paid Partner Content |
| Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion Oct 19 / Zacks.com - Paid Partner Content | Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study Oct 12 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights: Novartis, Zoom Video, FIS, 3M and TOTAL Oct 19 / Zacks.com - Paid Partner Content | Model N (MODN) Announces Upbeat Preliminary Results for Q4 Oct 09 / Zacks.com - Paid Partner Content |
| Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran Oct 19 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 84.14 |
| Today’s open | 84.93 |
| Day’s range | 84.04 - 84.61 |
| Volume | 1,110,855 |
| Average volume (3 months) | 1,736,341 |
| Market cap | $197.4B |
Data as of 3:42pm ET, 10/22/2020
Growth & Valuation
| Earnings growth (last year) | -43.54% |
| Earnings growth (this year) | +6.42% |
| Earnings growth (next 5 years) | +10.35% |
| Revenue growth (last year) | -8.60% |
| P/E ratio | 26.9 |
| Price/Sales | 4.62 |
| Price/Book | 3.52 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | +1.26 | +1.61% |
| PFEPfizer | +0.41 | +1.11% |
| ABBVAbbVie | +1.42 | +1.71% |
| AZNAstraZeneca | +0.37 | +0.72% |
Data as of 3:42pm ET, 10/22/2020
Financials
| Next reporting date | October 27, 2020 |
| EPS forecast (this quarter) | $1.45 |
| Annual revenue (last year) | $47.5B |
| Annual profit (last year) | $7.0B |
| Net profit margin | 15.04% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Basel, Basel-stadt (basle Town) |
Forecasts
